Business
Aeterna Zentaris Announces Top-Line Data from the Perifosine Phase 3 Trial in Refractory Advanced Colorectal Cancer
QUÉBEC CITY, April 2, 2012 /CNW Telbec/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX:&#...
About this update from Cosciens Biopharma Inc.
[{"type":"text","content":"\n\n\n\n\n\nQUÉBEC CITY, April 2, 2012 /CNW Telbec/ - Aeterna Zentaris Inc. (NASDAQ:\n AEZS) (TSX: AEZ) (the \"Company\") today announced that the Phase 3\n \"X-PECT\" (Xeloda® + Perifosine Evaluation in Colorectal cancer\n Treatment) clinical trial evaluating perifosine + capecitabine\n (Xeloda®) in patients with refractory advanced colorectal cancer did\n not meet the primary endpoint of improving overall survival versus\n capecitabine + placebo. The trial involving 468 patients in 65 sites in\n the U.S was conducted by the Company's North American licensee partner,\n Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX).\n\n\nJuergen Engel, Ph.D., Aeterna Zentaris President and Chief Executive\n Officer, commented, \"Although we are obviously very disappointed that\n the trial did not meet its primary endpoint, I would like to thank all\n those involved in this trial for their dedicated work. We are currently\n conducting further data analyses in collaboration with our licensee\n partners, in order to determine the future development strategy for\n perifosine. Our other ongoing late-stage programs with AEZS-108 and\n AEZS-130, as well as earlier-stage programs from our deep pipeline will\n continue as planned, with a sufficient cash position to pursue these\n programs for more than the next 12 months.\"\n\n\nThe Company will host a conference call and webcast later today, Monday,\n April 2, 2012 at 10:00 a.m. (Eastern). Participants may access the live\n webcast through the Company's website at www.aezsinc.com in the \"Newsroom\" section, or by telephone: in Canada, (514) 807-9895\n or (647) 427-7450, outside Canada, (888) 231-8191. A replay of the\n webcast will also be available on the Company's website for a period of\n 15 days.\n\n\nAbout Aeterna Zentaris Inc.\n\n\nAeterna Zentaris is a late-stage oncology drug development company\n currently investigating potential treatments for various cancers. The\n Company's innovative approach of \"personalized medicine\" means\n tailoring treatments to a patient's specific condition and to unmet\n medical needs. Aeterna Zentaris' deep pipeline is drawn from its\n proprietary discovery unit providing the Company with constant and\n long-term access to state-of-the-art therapeutic options. For more\n information please visit www.aezsinc.com.\n\n\nForward-Looking Statement...